Navigation Links
OncoMed Pharmaceuticals Completes Series B Financing
Date:11/4/2008

ors. OMP-21M18 targets a major cancer stem cell pathway, and is a part of OncoMed's collaboration with GlaxoSmithKline. The Phase I clinical trial is designed to evaluate the safety of escalating doses of OMP-21M18 in patients with solid tumors who have received previous treatment. Pharmacokinetics and initial indications of efficacy will also be assessed. OMP-21M18 is the first anti-cancer stem cell antibody against this novel target critical to cancer stem cells growth and development.

Cancer stem cells, a small subset of cells found in tumors, have the capacity to self-renew and differentiate, initiate and drive tumor growth, recurrence and metastasis. Also termed "tumor-initiating cells", these cells were discovered by OncoMed's scientific founders in breast cancer and have subsequently been identified in many other types of solid tumors including: colon, head and neck, lung, prostate, glioblastoma and pancreatic. Cancer stem cells appear to be preferentially resistant to both standard chemotherapy and radiotherapy. OncoMed's strategy is to improve cancer treatment by specifically targeting the key biologic pathways critical for the activity and survival of cancer stem cells. OncoMed's antibodies targeting cancer stem cell proteins have the potential to be developed against a range of solid tumor types such as pancreatic, breast, colorectal and lung cancers.

In conjunction with the financing, Denise Pollard-Knight, Ph.D., Managing Director of Nomura Phase4 Ventures, will join OncoMed's Board of Directors.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastases. A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal a
'/>"/>

SOURCE OncoMed Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
2. Genesis Pharmaceuticals Launches New Corporate Website
3. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
4. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
5. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
6. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
7. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
9. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
11. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015 ImmunoCellular Therapeutics, Ltd. ... Gengos , President and Chief Executive Officer, will ... DATE:  Thursday, May 7, 2015     TIME:  11:30 ... > click the red "register/ watch presentations" ... interactive online event where investors are invited to ...
(Date:5/5/2015)... Oakland, CA (PRWEB) May 05, 2015 ... Database technology, today announced that its flagship product, AllegroGraph, ... recent Graph Database Market Update report. AllegroGraph ... by leveraging the W3C industry standards. Graph databases are skyrocketing ... two years, according to a recent DBMS ranking ...
(Date:5/5/2015)... , May 5, 2015 CytomX, a biotechnology ... today announced that Sean McCarthy , D. Phil., ... Antibody Day in New York ... McCarthy will present an overview of CytomX,s Probody pipeline, ... conjugate programs. About CytomX Therapeutics CytomX ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 ... Hannifin distributor, announces the launch of http://www.cng.exoticautomation.com ... operators with a convenient way to purchase genuine ... products . , The new website provides ... vehicles with direct access to high performance products ...
Breaking Biology Technology:ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3Exotic Automation & Supply Launches Ecommerce Website 2
... Vermillion, Inc. (NASDAQ: VRML ), a molecular ... Trademark Office (USPTO) has issued a notice of allowance for ... claims cover the biomarker alpha1beta glycoprotein and biomarker combinations that ... "This will be our third patent for biomarkers that ...
... in hospitals is increasing. Bacteria acquire resistance to antibiotics ... genes, either from the surrounding environment or from other ... research (University of Lisbon) and the Instituto Gulbenkian de ... resistance are playing out in the bacterium Escherichia ...
... signals, for the first time, to assist in braking, ... to the thousands of car accidents that are caused ... technique that attaches electrodes to the scalp , the ... traffic sensors, could detect a driver,s intention to break ...
Cached Biology Technology:Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent 2Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent 3Bacterial resistance to antibiotics: The more they resist, the more they divide 2Put the brakes on using your brain power 2
(Date:4/9/2015)... JOSE, Calif. , April 9, 2015 ... human interface solutions, announced today that it will report ... on Thursday, April 23, 2015, after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... German . , Berlin, 2 September 2009 - ... ecosystems - from forests and mangroves to wetlands and river ... change and climate-proofing vulnerable economies. This is among the ... Economics of Ecosystems and Biodiversity (TEEB), a project launched by ...
... JACKSONVILLE, Fla. In a biological rendition of fiction,s ... the Mayo Clinic campus in Florida and Harvard Medical School ... development can actually spur the spread of tumors. ... Molecular and Cellular Biology , found that FOXO3a, a transcription ...
... that comes to mind when people think of Alzheimer,s disease, ... and France, this might change. That,s because these researchers have ... might be the key that unlocks an entirely new class ... report published online in The FASEB Journal ( ...
Cached Biology News:Time to tap climate change-combating potential of the world's ecosystems 2Time to tap climate change-combating potential of the world's ecosystems 3Time to tap climate change-combating potential of the world's ecosystems 4Time to tap climate change-combating potential of the world's ecosystems 5Mayo Clinic researchers find that protein believed to protect against cancer has a Mr. Hyde side 2Scientists begin to untangle root cause of Alzheimer's disease 2
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... anti-phospho-FAK (Ser843) Immunogen: ... region encompassing the human, mouse, and ... Accession Number: NM_153831 ... evaluated by immunoblot. ...
Biology Products: